Antibody-drug conjugates (ADCs) represent a significant breakthrough in oncology, offering targeted treatments, especially for lung cancer. In this insightful interview with Dr. Nicolas Girard, Head ...
The U.S. Food and Drug Administration (FDA) has approved Thermo Fisher’s Oncomine Dx Target Test, a next-generation sequencing (NGS)-based companion diagnostic, to identify patients eligible for ...
Researchers at Weill Cornell Medicine have made a breakthrough in the fight against hepatocellular carcinoma (HCC), by identifying a biomarker that could predict which patients are more likely to ...
The US FDA has approved zolbetuximab-clzb (VYLOY) as a first-line targeted therapy, in combination with chemotherapy, for the treatment of adults with advanced gastric and GEJ cancer. This marks a ...